Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicentre, retrospective of natural outcomes of new-onset inflammatory bowel disease among multiple sclerosis patients

Next Previous
Trial Profile

A multicentre, retrospective of natural outcomes of new-onset inflammatory bowel disease among multiple sclerosis patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anti CD20 antibody (Primary) ; Natalizumab (Primary) ; Sphingosine 1 phosphate receptor modulators (Primary) ; Tumour necrosis factor modulators (Primary) ; Vedolizumab (Primary)
  • Indications Inflammatory bowel diseases; Multiple sclerosis
  • Focus Therapeutic Use

Most Recent Events

  • 21 Dec 2021 New trial record
  • 27 Oct 2021 Results presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top